Targeting tumor vasculature with an oncolytic virus.

[1]  K. Preissner,et al.  Reciprocal coupling of coagulation and innate immunity via neutrophil serine proteases , 2010, Nature Medicine.

[2]  G. Hall,et al.  Antiangiogenic cancer therapy combined with oncolytic virotherapy leads to regression of established tumors in mice. , 2010, The Journal of clinical investigation.

[3]  H. Atkins,et al.  Double trouble for tumours: exploiting the tumour microenvironment to enhance anticancer effect of oncolytic viruses. , 2010, Cytokine & growth factor reviews.

[4]  D. Kirn,et al.  Targeted and armed oncolytic poxviruses: a novel multi-mechanistic therapeutic class for cancer , 2009, Nature Reviews Cancer.

[5]  F. Errington,et al.  Oncolytic viruses: a novel form of immunotherapy , 2008, Expert review of anticancer therapy.

[6]  D. Kirn,et al.  The targeted oncolytic poxvirus JX-594 demonstrates antitumoral, antivascular, and anti-HBV activities in patients with hepatocellular carcinoma. , 2008, Molecular therapy : the journal of the American Society of Gene Therapy.

[7]  Roberto Cattaneo,et al.  Reprogrammed viruses as cancer therapeutics: targeted, armed and shielded , 2008, Nature Reviews Microbiology.

[8]  D. Sze,et al.  Use of a targeted oncolytic poxvirus, JX-594, in patients with refractory primary or metastatic liver cancer: a phase I trial. , 2008, The Lancet. Oncology.

[9]  G. McFadden,et al.  Innate immunity, tumor microenvironment and oncolytic virus therapy: friends or foes? , 2008, Current opinion in molecular therapeutics.

[10]  D. Kirn,et al.  Targeting of Interferon-Beta to Produce a Specific, Multi-Mechanistic Oncolytic Vaccinia Virus , 2007, PLoS medicine.

[11]  H. Atkins,et al.  Targeted inflammation during oncolytic virus therapy severely compromises tumor blood flow. , 2007, Molecular therapy : the journal of the American Society of Gene Therapy.

[12]  E. Galanis,et al.  Clinical trial results with oncolytic virotherapy: a century of promise, a decade of progress , 2007, Nature Clinical Practice Oncology.

[13]  J. Bell,et al.  Recent progress in the battle between oncolytic viruses and tumours , 2005, Nature Reviews Cancer.

[14]  J. Yélamos,et al.  Role of lipopolysaccharide and cecal ligation and puncture on blood coagulation and inflammation in sensitive and resistant mice models. , 2005, The American journal of pathology.

[15]  R. Lechler,et al.  Inhibition of intravascular thrombosis in murine endotoxemia by targeted expression of hirudin and tissue factor pathway inhibitor analogs to activated endothelium. , 2004, Blood.

[16]  J. Bell,et al.  Getting oncolytic virus therapies off the ground. , 2003, Cancer cell.

[17]  W. Seeger,et al.  The role of CC chemokine receptor 2 in alveolar monocyte and neutrophil immigration in intact mice. , 2002, American journal of respiratory and critical care medicine.

[18]  F. Luscinskas.  Cytokines and Endothelial Cell Activation , 2001 .

[19]  Klaus Ley,et al.  Physiology of Inflammation , 2001, Methods in Physiology Series.

[20]  S. Stacker,et al.  Viral Vascular Endothelial Growth Factor Plays a Critical Role in Orf Virus Infection , 2000, Journal of Virology.

[21]  H. Castro,et al.  Bothroalternin, a thrombin inhibitor from the venom of Bothrops alternatus. , 1998, Toxicon : official journal of the International Society on Toxinology.

[22]  P. Ward,et al.  Mechanisms of endothelial cell injury in acute inflammation. , 1994, Shock.

[23]  M. Gimbrone,et al.  Neutrophil-mediated damage to human vascular endothelium. Role of cytokine activation. , 1993, The American journal of pathology.

[24]  P. Leder,et al.  An eosinophil-dependent mechanism for the antitumor effect of interleukin-4. , 1992, Science.

[25]  E. De Clercq,et al.  Sulfated polysaccharides are potent and selective inhibitors of various enveloped viruses, including herpes simplex virus, cytomegalovirus, vesicular stomatitis virus, and human immunodeficiency virus , 1988, Antimicrobial Agents and Chemotherapy.